MYC and neoplasm: We observed that in bone marrow, in both groups of mice that received MYC and LMP2A/MYC primary tumor cells, the percentage of B220-positive tumor cells was significantly decreased with TAK-659 treatment, but this decrease was much more pronounced in the mice with LMP2A/MYC cells (from 47% to 17% in MYC tumor cell recipients and from 60% to less than 10% in LMP2A/MYC tumor recipients) (Fig. 6A, BM graph).